Schwan identified protectionism by the United States and China as the firm’s biggest geopolitical worry.
Keystone-SDA
The Swiss pharmaceutical company Roche is increasingly concerned by protectionism in the United States and China. At the Swiss Economic Forum (SEF) in Interlaken on Thursday, Roche Chair Severin Schwan hit out at US tariff policies, likening them to “blackmail”.
Listen to the article
Listening the article
Toggle language selector
English (US)
English (British)
Generated with artificial intelligence.
This content was published on
June 5, 2026 – 09:28
+ Get the most important news from Switzerland in your inbox
“Our main concern at the moment is the rise of protectionism in our most important markets, the United States and China”, said Schwan at the Swiss Economic Forum (SEF) in Interlaken.
The US and China are using their dominant market positions to ensure that value creation takes place within their respective countries. “This is completely disrupting our structures,” he said.
In December 2025, Roche and Novartis, along with other global pharmaceutical giants, reached an agreement with the US government. This obliges Roche subsidiary Genentech, for example, to lower the prices of certain pharmaceutical products.
More
More
Medicine access
Drugmakers reassess Europe as Trump overhauls drug-pricing rules
This content was published on
Mar 20, 2026
President Trump’s drug-pricing overhaul has triggered an earthquake in Europe as drugmakers scramble to protect their bottom lines.
Read more: Drugmakers reassess Europe as Trump overhauls drug-pricing rules
Roche has also announced investments of around $50 billion in the US. In return, it has been promised a three-year exemption from customs duties on pharmaceutical products in the US.
Schwan said this agreement is not a real deal, but more akin to blackmail. “It’s the law of the strongest,” he said.
More
More
US imposes 15% tariff on Swiss pharma products
This content was published on
Apr 3, 2026
American President Donald Trump has announced tariffs of up to 100% on the import of patented medicines into the US.
Read more: US imposes 15% tariff on Swiss pharma products
Faced with the threat of higher US tariffs, Roche acted like many companies in other sectors, he said.
“In the short term, we have increased our production and exported our products to the United States on a larger scale. In the long term, we must now reorganise our supply chains and become less dependent on politics in our main markets,” he stressed, adding that this will be to the detriment of other countries, including Switzerland.
More
More
Drug pricing
The art of the deal: what are Trump’s pharma announcements really worth?
This content was published on
Feb 18, 2026
Big Pharma announced a series of groundbreaking agreements with the White House in 2025. But how much of it is just for show?
Read more: The art of the deal: what are Trump’s pharma announcements really worth?
Translated from French with AI/sb
How we work
We select the most relevant news for an international audience and use automatic translation tools to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication.
Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.
If you have any questions about how we work, write to us at english@swissinfo.ch.
Articles in this story